Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Research & Development (2020 - 2025)

Bioventus (BVS) has disclosed Research & Development for 6 consecutive years, with $2.9 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 23.94% year-over-year to $2.9 million, compared with a TTM value of $12.9 million through Sep 2025, down 5.62%, and an annual FY2023 reading of $13.4 million, down 43.63% over the prior year.
  • Research & Development was $2.9 million for Q3 2025 at Bioventus, down from $3.2 million in the prior quarter.
  • Across five years, Research & Development topped out at $7.1 million in Q4 2021 and bottomed at $947000.0 in Q2 2021.
  • Average Research & Development over 5 years is $4.2 million, with a median of $3.8 million recorded in 2023.
  • The sharpest move saw Research & Development crashed 55.87% in 2021, then skyrocketed 631.57% in 2022.
  • Year by year, Research & Development stood at $7.1 million in 2021, then decreased by 16.29% to $5.9 million in 2022, then tumbled by 45.14% to $3.3 million in 2023, then rose by 17.81% to $3.8 million in 2024, then dropped by 23.94% to $2.9 million in 2025.
  • Business Quant data shows Research & Development for BVS at $2.9 million in Q3 2025, $3.2 million in Q2 2025, and $3.0 million in Q1 2025.